From bioinformatics analysis
to proteomic validation.
ErVaccine Technologies develops breakthrough immunotherapies combining cancer vaccines and T-cell therapies based on the identification of new families of tumor antigens.
We focus on non-conventional cancer epitopes with the aim of addressing a high medical need in cold tumors not responding to immune checkpoint blockade.
We are dedicated to discover more accurate tumor epitopes that are shared between patients. Our approach is based on new bioinformatics algorithms to identify potential epitopes that are validated by proteomics and immunology assays: from bioinformatics to proteomics.